Our findings provide insights into understanding the mechanisms in the development of NPC, where the dysregulation of alternative splicing as a critical posttranscriptional regulation of gene expression plays an important role; and our findings also provide insights into the development of clinical biomarkers and therapeutic approaches focusing on GOLIM4, RBFOX2, and vesicular transport pathway involving RAB26, of which clinical values await further validations in more patient cohorts. This evidence concerns the gene GOLIM4 and nasopharyngeal carcinoma.